Actimed Therapeutics Limited

Other

B.r.a.h.m.s Gmbh

Psioxus Therapeutics Limited

Par Pharmaceuticals, Inc.

CharitÉ—universitaetsmedizn Berlin

Charité – Universitätsmedizin Berlin

Coats, Andrew J.s.

Stefan Anker

Jochen Springer

Andrew J S Coats

Andreas Bergmann

Joachim Struck

Nils G Morgenthaler

Jana Papassotiriou

Andrew Js Coats

John William Beadle

Andrew Coats

Andrew JS Coats

The present invention relates to S-enantiomerically enriched compositions of beta blockers and uses thereof, including uses of the beta blocker compositions for treating amyotrophic lateral sclerosis. The beta blocker compositions can also be used for preventing loss of lean mass, preventing body weight loss in subjects, improving quality of life in subjects, and prolonging survival in amyotrophic lateral sclerosis patients. The beta blocker can be oxprenolol or a pharmaceutically acceptable salt thereof.

S-enantiomerically enriched compositions of beta blockers for treating amyotrophic lateral sclerosis

The present invention relates to compositions of S-enantiomer enriched oxprenolol and their use in treating cancer and treating or preventing, in cancer patients, cachexia, body weight loss, lean body mass loss and adipose tissue loss, and improving quality of life and prolonging survival of cancer patients.

Oxprenolol compositions for treating cancer

The use of S-enantiomerically enriched compositions of beta blockers for treating muscle weakness. The beta blocker can be oxprenolol or a pharmaceutically acceptable salt thereof.

S-enantiomerically enriched compositions of beta blockers for treating muscle weakness

The present invention is directed to selective AT2 receptor agonist or a pharmaceutically acceptable salt thereof for use in treatment of cachexia, preferably for use in treatment of cancer cachexia.

Selective AT2 receptor agonists for use in treatment of cachexia

The present invention provides a means for prevention and treatment of sarcopenia by administration of a substance that both reduces the sensibility of beta-adrenergic receptors and of 5-HT1a receptors. (S)-pindolol, (S)-propanol, tertalol, or bopindolol are preferred for this purpose.

Prevention and treatment of sarcopenia

The invention concerns the therapy with a cardiac resynchronization device (CRT) and/or therapy with an automated internal cardiac defibrillator (ICD) for treating patients with any cancer or patients with cachexia due to acute or chronic illness other than cardiac illness, including malignant tumor disease, COPD, chronic renal failure, liver cirrhosis, chronic infections, and/or AIDS. Areas of application are the life sciences, in particular medicine and medical technology.

Method for enhancing the performance and general condition of a subject

The present invention relates to an in vitro method for medical diagnosis, prognosis and therapy follow-up for patients having a cardiac disease or being suspected of developing or having a cardiac disease comprising the steps of: providing a sample of a patient having a cardiac disease or being suspected of developing or having a cardiac disease, determining amino-terminal proANp or partial peptides thereof having from 12 to 98 amino acids in said sample using at least one antibody that binds specifically to a partial sequence of amino-terminal proANP, attributing the determined amino-terminal proANP level or the level of partial peptides thereof to a clinical picture wherein the attribution is carried out independent of the BMI of the patient. The present invention further concerns a rapid test assay and a kit for conducting the method of the present invention and the use of antibodies suitable for the method and assays according to the present invention.

Method for determining amino-terminal proANP in patients having a cardiac disease or being suspected of developing or having a cardiac disease

A method of treating patients in need of heart beat regulation or for preventing the development of cardiac arrhythmias, wherein the patients are not suffering from cardiac illness, by regulating heart beat using a cardiac pacemaker and reducing patient risk of developing a ventricular arrhythmia, wherein the risk is associated with an underlying patient illness, and wherein the patient does not suffer from cardiac illness, by regulating the patient's heart beat using a cardiac pacemaker.

The present invention relates to improving the heart function, the survival and/or the treatment of heart insufficiency using megestrol acetate (Megace&#xae;; MA) in patients with heart insufficiency and after a myocardial infarction.

Growing community of inventors

Berlin, Germany

Stefan Anker